Budigalimab, Sorafenib STADA 200 mg Filmtabletten, Livmoniplimab, Kisplyx 4 mg hard capsules
M24-147
Phase 2 small_molecule active
Quick answer
Budigalimab, Sorafenib STADA 200 mg Filmtabletten, Livmoniplimab, Kisplyx 4 mg hard capsules for Hepatocellular Carcinoma is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active